Collegium Pharmaceutical (COLL) Raised to Strong-Buy at BidaskClub
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.
COLL has been the subject of several other research reports. Piper Jaffray Companies restated a “buy” rating and issued a $14.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 price target for the company. Jefferies Group restated a “buy” rating and issued a $15.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, September 21st. Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.33.
Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $19.06 on Friday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92. The company has a market cap of $619.01, a P/E ratio of -6.40 and a beta of 0.41.
Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. During the same period in the prior year, the business earned ($1.13) earnings per share. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. research analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.
In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alison B. Fleming sold 4,601 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,058,630 shares of company stock valued at $18,264,360. 25.76% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in COLL. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth approximately $125,000. Credit Suisse AG lifted its position in Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Collegium Pharmaceutical in the 3rd quarter worth approximately $192,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth approximately $198,000. Institutional investors own 79.98% of the company’s stock.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.